Understand the source comparison
ARA-290 News 2026: [Research Compound] Comparison
Researchers evaluating tissue-protective peptides need clarity on mechanism, selectivity, and clinical-stage evidence. The following comparison positions ARA-290 against related compounds used in neuroprotection and metabolic research. ARA-290 Selective tissue
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers evaluating tissue-protective peptides need clarity on mechanism, selectivity, and clinical-stage evidence. The following comparison positions ARA-290 against related compounds used in neuroprotection and metabolic research.
- ARA-290
- Selective tissue-protective EPOR agonist (βc-EPOR complex); activates JAK2-STAT5, suppresses NF-κB
- None—does not bind alpha homodimer EPOR
- Phase IIb (diabetic nephropathy, neuropathy)
- Small-fiber neuropathy, renal protection, ischemia-reperfusion injury
- First compound to separate EPO's cytoprotection from erythropoiesis—critical for mechanistic studies without thrombotic confounders
- Erythropoietin (EPO)
- Dual-action: stimulates red blood cell production via alpha homodimer + tissue protection via βc-EPOR
- High—primary mechanism is hematopoiesis
- FDA-approved (anemia); investigational for neuroprotection
- Anemia of chronic disease, investigational stroke/TBI
- Tissue-protective effects exist but are masked by hematocrit elevation, hypertension, thrombosis risk—limits research utility
- BPC-157 Peptide
- Gastric pentadecapeptide; promotes angiogenesis, modulates nitric oxide pathways
- None
- Preclinical only
- Tendon/ligament repair, GI mucosal healing, soft tissue injury
- Promising preclinical data but lacks Phase II human trials—mechanism less defined than ARA-290's receptor-mediated pathway
- Thymosin Alpha 1 Peptide
- Immunomodulator; enhances T-cell maturation, cytokine production
- FDA-approved (hepatitis); investigational (sepsis)
- Immune dysfunction, chronic viral infection, adjunct cancer therapy
- Established safety profile but distinct mechanism—primarily immunologic rather than direct tissue cytoprotection
- Cerebrolysin
- Porcine brain-derived peptide mixture; neurotrophic and neuroprotective effects
- Phase III/IV (stroke, dementia)
- Post-stroke recovery, cognitive impairment, TBI
- Contains multiple active peptides—less mechanistically defined than ARA-290; efficacy debated in Western neurology
- ARA-290's advantage lies in its single, well-characterized target and the absence of erythropoietic side effects. Researchers studying tissue repair no longer need to account for hematocrit changes, dose-limiting thrombosis, or hypertension—confounders that plagued EPO neuroprotection trials. For labs prioritizing mechanistic clarity and translatability, ARA-290 represents the current standard in selective EPOR research.